DPP4-directed therapeutic strategies for MERS-CoV
- 1 February 2014
- journal article
- other
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 14 (2) , 100-101
- https://doi.org/10.1016/s1473-3099(13)70696-0
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infectionThe Lancet Infectious Diseases, 2013
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCNature, 2013
- Recent patents of dipeptidyl peptidase IV inhibitorsExpert Opinion on Therapeutic Patents, 2011
- Transforming Growth Factor-β: Activation by Neuraminidase and Role in Highly Pathogenic H5N1 Influenza PathogenesisPLoS Pathogens, 2010
- DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosisFrontiers in Bioscience-Landmark, 2008